Table S1. Capecitabine dose adjustments for non-hematologic AE’s.

AE incidence	Grade 2	Grade 3	Grade 4
1st appearance	Interrupt treatment until resolved to grade 0–1, then continue at same dose with prophylaxis where possible	Interrupt treatment until resolved to grade 0–1, then continue at 75% of original dose with prophylaxis where possible	Discontinue treatment unless Investigator considers it to be in the best interests of the patient to continue at 50% of original dose, once toxicity has resolved to grade 0–1
2nd appearance of same toxicity	Interrupt treatment until resolved to grade 0–1, then continue at 75% of original dose	Interrupt treatment until resolved to grade 0–1, then continue at 50% of original dose	–
3rd appearance of same toxicity	Interrupt treatment until resolved to grade 0–1, then continue at 50% of original dose	Discontinue treatment permanently (off study) unless it is considered to be by the investigator in the best interest of the patient to stay on treatment	–
4th appearance of same toxicity	Discontinue treatment permanently (off study) unless it is considered to be by the investigator in the best interest of the patient to stay on treatment	–	–